Antimicrobial Activity, AME Resistance, and A-Site Binding Studies of Anthraquinone–Neomycin Conjugates
- 17 February 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 3 (3) , 206-215
Abstract
The antibacterial effects of aminoglycosides are based on their association with the A-site of bacterial rRNA and interference with the translational process in the bacterial cell, causing cell death. The clinical use of aminoglycosides is complicated by resistance and side effects, some of which arise from their interactions with the human mitochondrial 12S rRNA and its deafness-associated mutations, C1494U and A1555G. We report a rapid assay that allows screening of aminoglycoside compounds to these classes of rRNAs. These screening tools are important to find antibiotics that selectively bind to the bacterial A-site rather than human, mitochondrial A-sites and its mutant homologues. Herein, we report our preliminary work on the optimization of this screen using 12 anthraquinone–neomycin (AMA−NEO) conjugates against molecular constructs representing five A-site homologues, Escherichia coli, human cytosolic, mitochondrial, C1494U, and A1555G, using a fluorescent displacement screening assay. These conjugates were also tested for inhibition of protein synthesis, antibacterial activity against 14 clinically relevant bacterial strains, and the effect on enzymes that inactivate aminoglycosides. The AMA–NEO conjugates demonstrated significantly improved resistance against aminoglycoside-modifying enzymes (AMEs), as compared with NEO. Several compounds exhibited significantly greater inhibition of prokaryotic protein synthesis as compared to NEO and were extremely poor inhibitors of eukaryotic translation. There was significant variation in antibacterial activity and MIC of selected compounds between bacterial strains, with Escherichia coli, Enteroccocus faecalis, Citrobacter freundii, Shigella flexneri, Serratia marcescens, Proteus mirabilis, Enterobacter cloacae, Staphylococcus epidermidis, and Listeria monocytogenes exhibiting moderate to high sensitivity (50–100% growth inhibition) whereas Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiellla pneumoniae, and MRSA strains expressed low sensitivity, as compared to the parent aminoglycoside NEO.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (AI090048, AI114114)
- National Institute of General Medical Sciences (GM 097917)
This publication has 46 references indexed in Scilit:
- 6′′‐Thioether Tobramycin Analogues: Towards Selective Targeting of Bacterial MembranesAngewandte Chemie International Edition, 2012
- Effects of Altering Aminoglycoside Structures on Bacterial Resistance Enzyme ActivitiesAntimicrobial Agents and Chemotherapy, 2011
- Unusual regioversatility of acetyltransferase Eis, a cause of drug resistance in XDR-TBProceedings of the National Academy of Sciences, 2011
- Aminoglycoside modifying enzymesDrug Resistance Updates, 2010
- Microcalorimetric assay on the antimicrobial property of five hydroxyanthraquinone derivatives in rhubarb (Rheum palmatum L.) to Bifidobacterium adolescentisPhytomedicine, 2010
- Probing the Recognition Surface of a DNA Triplex: Binding Studies with Intercalator−Neomycin ConjugatesBiochemistry, 2010
- Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicityProceedings of the National Academy of Sciences, 2008
- Small molecules with antimicrobial activity against E. coli and P. aeruginosa identified by high‐throughput screeningBritish Journal of Pharmacology, 2006
- Analysis of the Contribution of Individual Substituents in 4,6-Aminoglycoside-Ribosome InteractionAntimicrobial Agents and Chemotherapy, 2005
- Structural origins of aminoglycoside specificity for prokaryotic ribosomesJournal of Molecular Biology, 2001